

VPA10803/003/001

Canaural ear drops, suspension for dogs and cats

Variation	Summary	Date
Vet - F.II.e.4 z)	VRA-R - Vet - F.II.e.4 z) - - Vet - F.II.e.4 z) - Change in shape or dimensions of the container or closure (immediate packaging) - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	05/09/25
Vet - F.II.d.2 b)	VRA-R - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	27/03/25
Vet - F.I.a.1 a)	VRA-S - Vet - F.I.a.1 a) - a) Introduction of a manufacturer of the active substance supported by an ASMF - F.I.a.1 a) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - Introduction of a manufacturer of the active substance supported by an ASMF	05/02/25
Vet - F.II.d.2 z)	VRA-S - Vet - F.II.d.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.2 z) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	26/06/24
B.I.a.1.b	II - B.I.a.1.b - b) Introduction of a manufacturer of the active substance supported by an ASMF - B.I.a.1.b - QUALITY CHANGES - ACTIVE SUBSTANCE - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - Introduction of a manufacturer of the active substance supported by an ASMF	17/01/23